Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$1.0 million.

  • Beam Therapeutics' Gains from Investment Securities fell 380370.37% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 8404.53%. This contributed to the annual value of $9.6 million for FY2024, which is 1606.46% up from last year.
  • Per Beam Therapeutics' latest filing, its Gains from Investment Securities stood at -$1.0 million for Q3 2025, which was down 380370.37% from $28000.0 recorded in Q2 2025.
  • Beam Therapeutics' Gains from Investment Securities' 5-year high stood at $60.9 million during Q4 2021, with a 5-year trough of -$12.5 million in Q4 2022.
  • Moreover, its 5-year median value for Gains from Investment Securities was $8.7 million (2023), whereas its average is $10.0 million.
  • In the last 5 years, Beam Therapeutics' Gains from Investment Securities skyrocketed by 376027.57% in 2022 and then crashed by 380370.37% in 2025.
  • Beam Therapeutics' Gains from Investment Securities (Quarter) stood at $60.9 million in 2021, then tumbled by 120.48% to -$12.5 million in 2022, then skyrocketed by 247.31% to $18.4 million in 2023, then crashed by 32.98% to $12.3 million in 2024, then crashed by 108.12% to -$1.0 million in 2025.
  • Its Gains from Investment Securities stands at -$1.0 million for Q3 2025, versus $28000.0 for Q2 2025 and $27000.0 for Q1 2025.